Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00789581 · ClinicalTrials.gov registry record · Phase 3
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
A Phase 3 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 3
- Development phase
- 614
- Enrollment target
NCT00789581 is a Phase 3 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 614 participants.
The verdict
NCT00789581, a Phase 3 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 614 participants
- Enrollment target
Study Summary
This is a randomized, Phase III, open-label, multicenter study.
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Ixabepilone (Ixempra)
- DRUG Paclitaxel (Taxol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 614 participants |
| Start Date | 2008-12 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00789581
The ClinicalTrials.gov registry entry for NCT00789581 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 614 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT00789581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00789581 about?
NCT00789581 is a clinical study titled "A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer". This is a randomized, Phase III, open-label, multicenter study.
What is the current status of trial NCT00789581?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 614 participants. The study started on 2008-12. Estimated completion is 2016-11.
What interventions are being tested in trial NCT00789581?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Ixabepilone (Ixempra) (DRUG), Paclitaxel (Taxol) (DRUG).
Who is sponsoring clinical trial NCT00789581?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.